FDA Adverse Event Injury Summary report: N

ALARIS SE PRIMARY INFUSION SET

MDR report key: 4072119 · Received August 27, 2014

Report

Report Number
9616066-2014-00913
Event Type
Injury
Date Received
August 27, 2014
Date of Event
June 11, 2014
Report Date
July 29, 2014
Manufacturer
CAREFUSION CORPORATION
Product Code
FPA
PMA / PMN Number
K931550
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
NURSE

Narratives

Additional Manufacturer Narrative · 1

(B)(4); SAMPLE INVOLVED IN THE EVENT WILL NOT BE RETURNED AS IT WAS NOT AVAILABLE. NO FAILURE INVESTIGATION COULD BE PERFORMED. DURING A SITE VISIT BY CAREFUSION REPRESENTATIVES, THE CUSTOMER INDICATED THAT THE RECENT INCREASE IN THE REPORTED DRUG REACTIONS APPEARS TO COINCIDE WITH SUMMER ENVIRONMENTAL TEMPERATURES. RECONSTITUTED DRUGS WERE NOT BEING STORED IN THE REFRIGERATOR DURING THIS TIME AS INDICATED IN THE DIRECTION FOR USE.

Description of Event or Problem · 1

THE CUSTOMER REPORTED THAT APPROXIMATELY 2 MONTHS AFTER CHANGING FROM HOSPIRA SETS TO CAREFUSION, THEY HAVE NOTICED AN INCREASE IN DOCETAXEL REACTIONS WITH THEIR PATIENTS. THE REPORT SUGGESTS THAT 20 TO 40 MINUTES INTO THE INFUSION THE PATIENT COMPLAINED OF DIFFICULTY BREATHING, SHORTNESS OF BREATH, GENERALLY NOT FEELING WELL AND LOW BLOOD PRESSURE. SANOFI (MANUFACTURER OF DOCETAXEL) HAS ADVISED THE CUSTOMER THAT THEY HAVE NOT SEEN ANY DEVIATIONS OR ANOMALIES IN THEIR MANUFACTURING RECORDS AND HAVE RECEIVED NO OTHER REPORTS OF AN INCREASE IN PATIENT REACTIONS TO DOCETAXEL. THE HOSPITAL HAS ALSO CONFIRMED THAT THERE HAVE BEEN NO OTHER CHANGES IN THEIR CLINICAL PRACTICE WITHIN THAT TIME.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
519694 ALARIS SE PRIMARY INFUSION SET IV INFUSION SET FPA CAREFUSION CORPORATION 72923E-006 UNK

Patients

Seq Age Sex Outcome Treatment
1 UNKNOWN Required Intervention ALARIS SE PUMP - SERIAL NUMBER UNKNOWN, THERAPY| DATE: